poisar

Stocks · News reference

BlossomHill Therapeutics Announces FDA Alignment on Phase 2 Dose for BH-30643

Fiscal.ai

BlossomHill Therapeutics has reached alignment with the U.S. Food and Drug Administration on a 50 mg twice-daily dose for the Phase 2 trial of its OMNI-EGFR inhibitor, BH-30643.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading